LAURUSLABS vs SHILPAMED: Stock Comparison
LAURUS LABS is the larger company by market capitalisation. LAURUS LABS shows a higher ROE and a higher ROCE, while SHILPA MEDICARE shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LAURUSLABS leads 5; SHILPAMED leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LAURUSLABS | SHILPAMED |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LAURUSLABS | SHILPAMED |
|---|---|---|
| Live Price | ₹1,969 | ₹961.15 |
| Day Change | 1.23% | 2.26% |
| Volume | 22.77 L | 14.72 L |
| 52-Week High | ₹1,955 | ₹980.1 |
| 52-Week Low | ₹823.1 | ₹259.5 |
| Distance from 52W High | 0.72% | -1.93% |
Valuation
| Metric | LAURUSLABS | SHILPAMED |
|---|---|---|
| Market Cap | ₹1.06 L Cr | ₹18,835 Cr |
| P/E Ratio | 97.3x | 63.36x |
| P/B Ratio | 20.07x | 7.27x |
| EPS | ₹5.37 | ₹3.32 |
| Book Value | ₹100.53 | ₹132.49 |
| Dividend Yield | 0.1% | 0.17% |
Growth
| Metric | LAURUSLABS | SHILPAMED |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.3% | 31.5% |
| EPS Growth (TTM YoY) | 19.4% | 644.6% |
| Qtr Sales Growth | -13.28% | -59.41% |
| Qtr Profit Growth | -19.92% | -35.65% |
Profitability & Leverage
| Metric | LAURUSLABS | SHILPAMED |
|---|---|---|
| ROE | 16.39% | 4.9% |
| ROCE | 13.2% | 5.01% |
| Net Margin | 13.76% | 15.82% |
| Operating Margin | 19.85% | 26.49% |
| Debt to Equity | 0.44x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | LAURUSLABS | SHILPAMED |
|---|---|---|
| Promoter Holding | 27.47%▼ 0.02 pp | 40.13% |
| FII Holding | 28%▲ 2.18 pp | 11.38%▲ 0.3 pp |
| DII Holding | 13.74%▼ 0.23 pp | 8.05%▼ 0.53 pp |
| Public Holding | 30.78%▼ 1.93 pp | 40.43%▲ 0.22 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LAURUS LABS and SHILPA MEDICARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.